

FOR IMMEDIATE RELEASE

Contact:

Johna Carufel

Business Services Manager

9001 Wesleyan Road, Suite 200

Indianapolis, IN 46268

Ph. (317) 569-9500 x 117

Fax (317) 569-9520

Cell (317) 201-8711

www.ansongroup.com

jcarufel@ansongroup.com

ANSON GROUP ASSISTS FRENCH PHARMACEUTICAL COMPANY IN INITIATION OF REGISTRATION TRIAL IN RHEUMATOID ARTHRITIS

(INDIANAPOLIS IN) August 17, 2011 – The Anson Group is pleased to announce that its client AB Science SA, a French pharmaceutical company headquartered in Paris, has successfully initiated a phase 2b/3 registration study of masitinib for the treatment of rheumatoid arthritis. AB Science is conducting this international, multi-location study to compare the safety and efficacy of masitinib to an existing treatment, methotrexate, for the treatment of patients with active rheumatoid arthritis that have demonstrated an inadequate response to methotrexate or other disease-modifying anti-rheumatic drugs. This study will involve approximately 450 patients at 90 sites throughout the world. AB Science is developing masitinib, a selective tyrosine kinase inhibitor that impacts activation and survival of mast cells, which play a role in rheumatoid arthritis.

AB Science is also conducting ongoing registration trials with masitinib in the U.S. and throughout the world for various oncology indications including pancreatic cancer, melanoma and gastrointestinal stromal tumors and in other non-oncology indications including severe asthma and multiple sclerosis.

The Anson Group has been acting as the U.S. Agent for AB Science, managing the company's interactions with multiple Review Divisions at the

Food and Drug Administration for all U.S. clinical studies required for masitinib. John Worzalla of the Anson Group has served as the lead advisor to AB Science since 2006 in regard to FDA regulations for filing investigational new drug applications (IND's).

In addition to human use, masitinib under the trade name of Kinavet CA-1[®] is prescribed for treating dogs with mast cell tumors. Dr. Michael Langley of the Anson Group, acting as the U.S. Agent to the FDA's Center for Veterinary Medicine, assisted AB Science in obtaining a Conditional Approval in the U.S. in December of 2010 for masitinib for treating dogs with cutaneous mast cell tumors.

About the Anson Group

Headquartered in Indianapolis Indiana, Anson Group is a woman-owned regulatory consulting firm that is a recognized industry leader in life sciences regulatory advisory and strategy services. Anson brings to its clients more than 15 years of experience supporting clients who produce medical devices, drugs, biologics, and combination products, engaging experienced industry experts who can tailor comprehensive enterprise regulatory strategies producing clearly defined action plans to address crucial issues throughout the product life cycle. Anson works with clients in the United States, Europe, and Asia, from global pharmaceutical manufacturers to small pre-IPO or VC biotechnology and medical device start-ups.

About AB Science and Masitinib

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signaling pathways within cells. Through these PKIs, the Company targets diseases with high unmet medical needs (cancer, inflammatory diseases and central nervous system diseases), in both human and veterinary medicines. AB Science has developed its own portfolio of molecules including masitinib, a new orally administered tyrosine kinase inhibitor that targets mast cells, important cells for immunity, as well as a limited number of kinases that play key roles in various cancers. Owing to its novel mechanism of action, masitinib

can be developed in a large number of conditions in oncology, in inflammatory diseases and in certain diseases of the central nervous system. Through its activity of inhibiting certain kinases that are essential in some oncogenic processes, masitinib may have an effect on tumor regression, alone or in combination with chemotherapy. Through its activity on the mast cell and certain kinases essential to the activation of the inflammatory cells and fibrosing tissue remodeling, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases.

Masitinib has already been registered in veterinary medicine in Europe (Masivet[®]) and in the U.S. (Kinavet CA-1[®]) for the treatment of mast cell tumors in dogs. AB Science is pursuing nine phase 3 studies in human medicine, including six studies on-going in pancreatic cancer, GIST, metastatic melanoma expressing JM mutation of c-Kit, mastocytosis, severe persistent asthma, and rheumatoid arthritis.